Patient Experience Data: US FDA’s Evidentiary Standards Should Reflect Intended Use
Executive Summary
Degree of rigor may vary depending upon intended use of the data throughout a drug’s lifecycle, stakeholders say in comments on FDA’s first patient-focused drug development draft guidance; industry and advocates push for clarity on interactions to discuss patient experience studies with FDA staff and the promotional implications of such data.
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
